---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-013842"
form_type: "8-K"
ticker: "MLAB"
cik: "0000724004"
company_name: "MESA LABORATORIES INC /CO/"
filed_at: "2022-05-31T23:59:59+00:00"
generated_at: "2026-06-25T06:03:26.341084+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mesa Labs reports Q4 GAAP operating loss of $110k; adjusted op income ex-unusual items up 31%

## Summary
- GAAP operating loss of $110k vs income of $4.3M a year ago; net loss $1.78M (-$0.34 diluted EPS).
- Non-GAAP adjusted operating income (AOI) rose 11% to $11.65M; AOI ex-unusual items up 31% to $13.57M.
- Total revenues grew 55% in Q4 to $58.9M, organic +12%; FY revenues up 38% to $184.3M, organic +13%.
- Clinical Genomics segment revenue $16.4M including $1.4M COVID; ex-COVID below plan, China lockdowns expected to impact Q1.
- FY23 guidance cautious: lower organic growth expected due to inflation, war in Europe, and Asia pandemic resurgence.

## SEC filing metadata
- accession: 0001437749-22-013842
- form_type: 8-K
- ticker: MLAB
- cik: 0000724004
- company_name: MESA LABORATORIES INC /CO/
- filed_at: 2022-05-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/724004/000143774922013842/0001437749-22-013842-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/724004/000143774922013842/mlab20220528_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-013842
- JSON: https://secwatch.observer/filing/0001437749-22-013842.json
- Plain text: https://secwatch.observer/filing/0001437749-22-013842.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.